Chemours (NYSE:CC) Given “Neutral” Rating at Mizuho

Chemours (NYSE:CC)‘s stock had its “neutral” rating reiterated by investment analysts at Mizuho in a research note issued on Wednesday, Benzinga reports. They presently have a $15.00 price target on the specialty chemicals company’s stock, down from their previous price target of $18.00. Mizuho’s price objective would indicate a potential upside of 13.95% from the stock’s current price.

Several other research analysts have also recently issued reports on CC. Weiss Ratings cut Chemours from a “sell (d)” rating to a “sell (d-)” rating in a research note on Thursday, August 6th. Truist Financial reduced their price objective on Chemours from $30.00 to $24.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Royal Bank Of Canada lowered Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 target price for the company. in a research report on Tuesday. Barclays assumed coverage on Chemours in a report on Monday. They issued an “equal weight” rating and a $16.00 target price for the company. Finally, UBS Group lowered their target price on Chemours from $18.00 to $16.00 and set a “neutral” rating for the company in a report on Monday, October 5th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Chemours presently has an average rating of “Hold” and a consensus target price of $18.09.

Chemours Price Performance

Chemours stock opened at $13.16 on Wednesday. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.66 and a quick ratio of 0.88. The stock has a market cap of $1.98 billion, a price-to-earnings ratio of -6.89 and a beta of 1.41. The firm has a 50-day moving average of $14.83 and a two-hundred day moving average of $19.03. Chemours has a 1 year low of $10.44 and a 1 year high of $28.67.

Chemours (NYSE:CC) last issued its earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 EPS for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.07). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%. The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.65 billion. During the same period last year, the business posted ($2.54) earnings per share. The business’s revenue was down 1.5% compared to the same quarter last year. On average, research analysts forecast that Chemours will post 0.87 earnings per share for the current year.

Insider Activity

In other Chemours news, CFO Shane Hostetter acquired 3,350 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were bought at an average cost of $14.94 per share, with a total value of $50,049.00. Following the completion of the acquisition, the chief financial officer directly owned 102,698 shares in the company, valued at $1,534,308.12. This represents a 3.37% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Calderon Gerardo Familiar acquired 1,935 shares of Chemours stock in a transaction that occurred on Wednesday, August 12th. The stock was acquired at an average cost of $15.53 per share, with a total value of $30,050.55. Following the purchase, the insider directly owned 58,547 shares of the company’s stock, valued at $909,234.91. This represents a 3.42% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have acquired 8,663 shares of company stock worth $130,601. Corporate insiders own 0.85% of the company’s stock.

Institutional Trading of Chemours

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. bought a new position in shares of Chemours in the 2nd quarter worth $34,000. Allworth Financial LP purchased a new stake in shares of Chemours during the 2nd quarter worth $51,000. State of Wyoming purchased a new stake in shares of Chemours during the 2nd quarter worth $67,000. Nykredit A S bought a new stake in Chemours during the second quarter valued at about $99,000. Finally, Parallel Advisors LLC boosted its position in Chemours by 10.9% during the first quarter. Parallel Advisors LLC now owns 5,366 shares of the specialty chemicals company’s stock valued at $118,000 after purchasing an additional 527 shares in the last quarter. Institutional investors own 76.26% of the company’s stock.

Trending Headlines about Chemours

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: BMO Capital reaffirmed its Buy rating on Chemours, providing some support for the stock and signaling that the firm sees longer-term value despite near-term operating challenges. BMO Capital Reaffirms Buy Rating
• Neutral Sentiment: Barclays initiated coverage at Equal Weight, suggesting a balanced risk-reward view rather than a clear bullish or bearish recommendation. Barclays Initiates Coverage
• Negative Sentiment: RBC downgraded Chemours to Sector Perform from Outperform and cut its price target to $14 from $22. RBC cited persistent weakness in titanium dioxide, or TiO2, and anticipated headwinds in the Thermal & Specialized Solutions segment through year-end. The downgrade reinforces concerns about weak demand and limited near-term earnings momentum. RBC Downgrades Chemours
• Negative Sentiment: A securities class action has been filed against Chemours and certain officers. The lawsuit alleges investors were harmed by disclosures concerning Opteon refrigerant aftermarket demand before an approximately 18% stock decline. Additional law firms are soliciting investors ahead of the December 7, 2026 lead-plaintiff deadline. The allegations have not been proven, but the litigation adds legal, reputational and potential financial overhang. Pomerantz Class Action Filing

Chemours Company Profile

The Chemours Company (NYSE: CC) is a global chemical company that develops, manufactures and distributes specialty chemical products used in a range of industrial and consumer applications. Its portfolio serves markets including coatings, plastics, automotive, refrigeration and air conditioning, electronics, telecommunications, energy, healthcare and general manufacturing.

Chemours operates through three primary business segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials.